Oral contraceptive therapy reduces serum relaxin‐2 in elite female athletes
article
OA: closed
CC0
AI-generated summary
Oral contraceptive therapy significantly reduced serum relaxin-2 levels in elite female athletes, particularly in those with high levels during the luteal phase.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
AIM: Recent investigations have demonstrated that athletes with high relaxin-2 levels have a high risk of anterior cruciate ligament injuries, while athletes taking oral contraceptives (OC) have low relaxin-2 levels. It has not yet been clarified whether taking OC reduces relaxin-2 levels. The purpose of this study was to investigate changes in relaxin-2 levels in athletes taking OC. METHODS: Levels of relaxin-2, estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone were measured in serum samples (n = 183) from 106 elite female athletes. Five athletes with serum relaxin-2 concentrations > 6 pg/mL during the luteal phase were recruited to assess the effect of OC therapy. RESULTS: Serum relaxin-2 concentrations were significantly higher during the luteal phase (n = 57) than in the follicular phase (n = 72), or in athletes on OC therapy (n = 10) (P < 0.001, P < 0.001 and P 6 pg/mL. In 23 athletes, serum relaxin-2 concentrations were measured during both the follicular and luteal phases, revealing that relaxin-2 levels were significantly higher in the luteal phase compared with the follicular phase. In 5 out of 23 athletes, serum relaxin-2 concentrations were > 6 pg/mL in the luteal phase and during the second cycle of OC therapy, relaxin-2 concentrations decreased dramatically to below the detection limit (0.26 pg/mL). CONCLUSIONS: High serum relaxin-2 concentrations were only detected during the luteal phase. In athletes with high relaxin-2 concentrations during the luteal phase, OC therapy decreased serum relaxin-2 levels.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (28)
- doi:10.1007/bf03262292 via openalex
- doi:10.3928/0147-7447-20031201-08 via openalex
- doi:10.1177/0363546511413378 via openalex
- doi:10.1136/bjsm.2008.048934 via openalex
- W169004228 via openalex
- W1270097368 via openalex
- doi:10.1159/000292408 via openalex
- doi:10.1177/03635465030310041701 via openalex
- doi:10.2147/ijwh.s14188 via openalex
- doi:10.1016/s0749-8063(98)70125-2 via openalex
- doi:10.1177/0363546514557240 via openalex
- W2309633087 via openalex
- W2320112291 via openalex
- W4387736309 via openalex
- doi:10.1111/sms.12149 via openalex
- doi:10.1097/00003086-200003000-00007 via openalex
- doi:10.1177/03635465020300020601 via openalex
- doi:10.1177/03635465980260050301 via openalex
- doi:10.1152/japplphysiol.00614.2001 via openalex
- doi:10.1177/0363546508330146 via openalex
- doi:10.1113/expphysiol.2011.057877 via openalex
- doi:10.1016/j.knee.2008.09.005 via openalex
- doi:10.1089/jwh.1998.7.343 via openalex
- doi:10.2165/11632800-000000000-00000 via openalex
- doi:10.1111/j.1600-0838.1998.tb00185.x via openalex
- doi:10.3928/0147-7447-20020601-18 via openalex
- doi:10.2165/00007256-200029050-00003 via openalex
- doi:10.1290/0512089.1 via openalex
Source provenance
- openalex
- last seen: 2026-05-10T11:26:23.695233+00:00
- unpaywall
- last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0
· commercial use OK